Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total value of $524,706.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $21,480.00.

Enliven Therapeutics Trading Down 10.0 %

ELVN stock traded down $2.41 during midday trading on Friday, hitting $21.74. 323,088 shares of the company’s stock were exchanged, compared to its average volume of 204,598. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The stock has a market capitalization of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. The business has a 50-day simple moving average of $24.66 and a two-hundred day simple moving average of $24.39.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Barclays PLC boosted its position in Enliven Therapeutics by 295.8% in the 3rd quarter. Barclays PLC now owns 56,217 shares of the company’s stock valued at $1,435,000 after buying an additional 42,012 shares during the period. First Turn Management LLC raised its position in Enliven Therapeutics by 29.5% in the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Enliven Therapeutics by 9.9% in the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after buying an additional 67,813 shares during the period. Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the third quarter worth about $5,998,000. Finally, Patient Square Capital LP acquired a new position in shares of Enliven Therapeutics during the third quarter worth about $2,313,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

ELVN has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. BTIG Research began coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target for the company. Finally, Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.